Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.
BACKGROUND: The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. OBJECTIVE: The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleos...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3903621?pdf=render |
| _version_ | 1830517808996286464 |
|---|---|
| author | Zhu-Qing Liu Ying-Chao Han Xi Zhang Li Chu Jue-Min Fang Hua-Xin Zhao Yi-Jing Chen Qing Xu |
| author_facet | Zhu-Qing Liu Ying-Chao Han Xi Zhang Li Chu Jue-Min Fang Hua-Xin Zhao Yi-Jing Chen Qing Xu |
| author_sort | Zhu-Qing Liu |
| collection | DOAJ |
| description | BACKGROUND: The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. OBJECTIVE: The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleoside transporter1 expression as a prognostic factor in pancreatic cancer receiving gemcitabine-based chemotherapy and to conduct a subsequent meta-analysis to quantify the overall prognostic effect. METHODS: Related studies were identified and evaluated for quality through multiple search strategies. Only studies analyzing pancreatic cancer receiving gemcitabine-based chemotherapy were eligible for inclusion. Data were collected from studies comparing overall, disease-free and progression-free survival (OS, DFS and PFS) in patients with low human equilibrative nucleoside transporter1 levels and those having high levels. The hazard ratio (HR) and its 95% confidence interval (95%CI) were used to assess the strength of associations. Hazard ratios greater than 1 reflect adverse survival associated with low human equilibrative nucleoside transporter1 levels. RESULTS: A total of 12 studies (n = 875) were involved in this meta-analysis (12 for OS, 5 for DFS, 3 for PFS). For overall and disease-free survival, the pooled HRs of human equilibrative nucleoside transporter1 were significant at 2.93 (95% confidence interval [95% CI], 2.37-3.64) and 2.67 (95% CI, 1.87-3.81), respectively. For progression-free survival, the pooled HR in higher human equilibrative nucleoside transporter1 expression in pancreatic cancer receiving gemcitabine-based chemotherapy was 2.76 (95% CI, 1.76-4.34). No evidence of significant heterogeneity or publication bias was seen in any of these studies. CONCLUSION: These results support the case for a low human equilibrative nucleoside transporter1 level representing a significant and reproducible marker of adverse prognosis in pancreatic cancer receiving gemcitabine-based chemotherapy. |
| first_indexed | 2024-12-22T04:08:17Z |
| format | Article |
| id | doaj.art-ab9885a8f12e4b07989576aebb37cdf9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T04:08:17Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ab9885a8f12e4b07989576aebb37cdf92022-12-21T18:39:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8710310.1371/journal.pone.0087103Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.Zhu-Qing LiuYing-Chao HanXi ZhangLi ChuJue-Min FangHua-Xin ZhaoYi-Jing ChenQing XuBACKGROUND: The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. OBJECTIVE: The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleoside transporter1 expression as a prognostic factor in pancreatic cancer receiving gemcitabine-based chemotherapy and to conduct a subsequent meta-analysis to quantify the overall prognostic effect. METHODS: Related studies were identified and evaluated for quality through multiple search strategies. Only studies analyzing pancreatic cancer receiving gemcitabine-based chemotherapy were eligible for inclusion. Data were collected from studies comparing overall, disease-free and progression-free survival (OS, DFS and PFS) in patients with low human equilibrative nucleoside transporter1 levels and those having high levels. The hazard ratio (HR) and its 95% confidence interval (95%CI) were used to assess the strength of associations. Hazard ratios greater than 1 reflect adverse survival associated with low human equilibrative nucleoside transporter1 levels. RESULTS: A total of 12 studies (n = 875) were involved in this meta-analysis (12 for OS, 5 for DFS, 3 for PFS). For overall and disease-free survival, the pooled HRs of human equilibrative nucleoside transporter1 were significant at 2.93 (95% confidence interval [95% CI], 2.37-3.64) and 2.67 (95% CI, 1.87-3.81), respectively. For progression-free survival, the pooled HR in higher human equilibrative nucleoside transporter1 expression in pancreatic cancer receiving gemcitabine-based chemotherapy was 2.76 (95% CI, 1.76-4.34). No evidence of significant heterogeneity or publication bias was seen in any of these studies. CONCLUSION: These results support the case for a low human equilibrative nucleoside transporter1 level representing a significant and reproducible marker of adverse prognosis in pancreatic cancer receiving gemcitabine-based chemotherapy.http://europepmc.org/articles/PMC3903621?pdf=render |
| spellingShingle | Zhu-Qing Liu Ying-Chao Han Xi Zhang Li Chu Jue-Min Fang Hua-Xin Zhao Yi-Jing Chen Qing Xu Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. PLoS ONE |
| title | Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. |
| title_full | Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. |
| title_fullStr | Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. |
| title_full_unstemmed | Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. |
| title_short | Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. |
| title_sort | prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin based chemotherapy a meta analysis |
| url | http://europepmc.org/articles/PMC3903621?pdf=render |
| work_keys_str_mv | AT zhuqingliu prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT yingchaohan prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT xizhang prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT lichu prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT jueminfang prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT huaxinzhao prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT yijingchen prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT qingxu prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis |